Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7608616 | GALT PHARMS | Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia |
Jun, 2028
(5 years from now) |
Drugs and Companies using QUAZEPAM ingredient
Market Authorisation Date: 27 December, 1985
Treatment: Method for treating insomnia while reducing the risk of an adverse drug interaction
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7651698 | GALT PHARMS | Prolonged release bioadhesive therapeutic systems |
Sep, 2022
(8 months ago) | |
US6916485 | GALT PHARMS | Prolonged release bioadhesive therapeutic systems |
Sep, 2022
(8 months ago) | |
US8518442 | GALT PHARMS | Prolonged release bioadhesive therapeutic systems |
Sep, 2022
(8 months ago) |
Drugs and Companies using MICONAZOLE ingredient
Market Authorisation Date: 16 April, 2010
Treatment: Treatment of oropharyngeal candidiasis
Dosage: TABLET;BUCCAL
5
United States
2
Germany
2
Cyprus
2
France
2
China
2
Denmark
2
Portugal
2
Spain
2
Japan
2
Austria
2
European Union
1
Canada
1
Israel
1
Hong Kong
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic